Pharmesis International Ltd.

As of June 30, 2020, Pharmesis International Ltd. carries a market capitalization of 7.26M, placing it among publicly traded companies globally. Its enterprise value stands at 8.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2020, Pharmesis International Ltd. has 23.00M shares outstanding.

These figures are as of June 30, 2020.

As of June 30, 2020, Pharmesis International Ltd. maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2020, Pharmesis International Ltd. recorded an income tax benefit of -54,638.59 rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on September 30, 2026, Pharmesis International Ltd.'s stock has declined approximately 78.16% over the past 52 weeks. The 50-day moving average sits at 0.34, while the 200-day moving average is 0.34.

As of June 30, 2020, Pharmesis International Ltd. holds 2.63M in cash and equivalents against 3.14M in total debt, resulting in a net debt position of 331,579.33. Total book value stands at 11.53M, with working capital of 1.36M providing operational flexibility.

These figures cover the twelve months ended June 30, 2020.

Pharmesis International Ltd.'s most recent stock split took place on August 27, 2015 with a 10:1 split ratio.